Cargando…

Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran

BACKGROUND: Since 2020, COVID-19 has become a global public health issue and has caused problems worldwide. This infection can lead to a fever and respiratory problems. Asymptomatic carriers of the virus are a significant part of the spread of the disease, so early screening and diagnosis of suspect...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmanzadeh, F, Malekpour, N, Faramarzi, A, Yusefzadeh, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426176/
https://www.ncbi.nlm.nih.gov/pubmed/37580701
http://dx.doi.org/10.1186/s12913-023-09868-9
_version_ 1785090001982193664
author Rahmanzadeh, F
Malekpour, N
Faramarzi, A
Yusefzadeh, H
author_facet Rahmanzadeh, F
Malekpour, N
Faramarzi, A
Yusefzadeh, H
author_sort Rahmanzadeh, F
collection PubMed
description BACKGROUND: Since 2020, COVID-19 has become a global public health issue and has caused problems worldwide. This infection can lead to a fever and respiratory problems. Asymptomatic carriers of the virus are a significant part of the spread of the disease, so early screening and diagnosis of suspected cases of COVID-19 are essential. Generally, standard diagnostic methods include lung imaging (CT), polymerase chain reaction (PCR), and corona antibody (IgM&IgG) testing. However, the costs of the above tests for the healthcare system cannot be ignored, and evaluating the incremental costs against the additional benefit is necessary. Therefore, this study aimed to determine the cost-effectiveness of diagnostic methods for COVID-19 patients. MATERIALS AND METHODS: In this research, an economic evaluation analysis was conducted to reveal the cost-effectiveness of the diagnostic strategies for COVID-19 from the service provider’s perspective. Basic information about the costs of CT, serology (IgG&IgM), and molecular (PCR) tests were collected from the Ministry of Health of Iran. The effectiveness data were calculated according to the sensitivity and specificity of the diagnostic tests for COVID-19. In this study, the incremental cost-effectiveness ratio (ICER) of the diagnostic strategies for COVID-19 was estimated, and the most cost-effective diagnostic strategy was determined. In calculating ICER and analyzing the sensitivity of the results, Treeage software was used. RESULTS: According to the calculated incremental effectiveness cost ratio for scenarios with 5, 10, and 50% prevalence of COVID-19 and according to the threshold defined by the World Health Organization, in the study, PCR, PCR, and IgG&IgM strategies are the most cost-effective diagnostic methods of the corona. Also, the results were not sensitive to the desired parameters based on the results of one-way sensitivity analysis. CONCLUSION: Nowadays there are various tests with different levels of accuracy in the diagnosis of COVID-19. In general, PCR tests are more cost-effective for low prevalence of Covid-19, while IgM&IgG tests are more cost-effective for high estimated prevalence. The results of this research can help policymakers and health system managers to validate the most accurate diagnostic method for COVID-19, considering the prevalence of the disease.
format Online
Article
Text
id pubmed-10426176
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104261762023-08-16 Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran Rahmanzadeh, F Malekpour, N Faramarzi, A Yusefzadeh, H BMC Health Serv Res Research BACKGROUND: Since 2020, COVID-19 has become a global public health issue and has caused problems worldwide. This infection can lead to a fever and respiratory problems. Asymptomatic carriers of the virus are a significant part of the spread of the disease, so early screening and diagnosis of suspected cases of COVID-19 are essential. Generally, standard diagnostic methods include lung imaging (CT), polymerase chain reaction (PCR), and corona antibody (IgM&IgG) testing. However, the costs of the above tests for the healthcare system cannot be ignored, and evaluating the incremental costs against the additional benefit is necessary. Therefore, this study aimed to determine the cost-effectiveness of diagnostic methods for COVID-19 patients. MATERIALS AND METHODS: In this research, an economic evaluation analysis was conducted to reveal the cost-effectiveness of the diagnostic strategies for COVID-19 from the service provider’s perspective. Basic information about the costs of CT, serology (IgG&IgM), and molecular (PCR) tests were collected from the Ministry of Health of Iran. The effectiveness data were calculated according to the sensitivity and specificity of the diagnostic tests for COVID-19. In this study, the incremental cost-effectiveness ratio (ICER) of the diagnostic strategies for COVID-19 was estimated, and the most cost-effective diagnostic strategy was determined. In calculating ICER and analyzing the sensitivity of the results, Treeage software was used. RESULTS: According to the calculated incremental effectiveness cost ratio for scenarios with 5, 10, and 50% prevalence of COVID-19 and according to the threshold defined by the World Health Organization, in the study, PCR, PCR, and IgG&IgM strategies are the most cost-effective diagnostic methods of the corona. Also, the results were not sensitive to the desired parameters based on the results of one-way sensitivity analysis. CONCLUSION: Nowadays there are various tests with different levels of accuracy in the diagnosis of COVID-19. In general, PCR tests are more cost-effective for low prevalence of Covid-19, while IgM&IgG tests are more cost-effective for high estimated prevalence. The results of this research can help policymakers and health system managers to validate the most accurate diagnostic method for COVID-19, considering the prevalence of the disease. BioMed Central 2023-08-14 /pmc/articles/PMC10426176/ /pubmed/37580701 http://dx.doi.org/10.1186/s12913-023-09868-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rahmanzadeh, F
Malekpour, N
Faramarzi, A
Yusefzadeh, H
Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran
title Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran
title_full Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran
title_fullStr Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran
title_full_unstemmed Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran
title_short Cost-effectiveness analysis of diagnostic strategies for COVID-19 in Iran
title_sort cost-effectiveness analysis of diagnostic strategies for covid-19 in iran
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426176/
https://www.ncbi.nlm.nih.gov/pubmed/37580701
http://dx.doi.org/10.1186/s12913-023-09868-9
work_keys_str_mv AT rahmanzadehf costeffectivenessanalysisofdiagnosticstrategiesforcovid19iniran
AT malekpourn costeffectivenessanalysisofdiagnosticstrategiesforcovid19iniran
AT faramarzia costeffectivenessanalysisofdiagnosticstrategiesforcovid19iniran
AT yusefzadehh costeffectivenessanalysisofdiagnosticstrategiesforcovid19iniran